Kornimate/medical-research-clean huggingface dataset:
evaluation of the benefits of adaptive physical activity in children and adolescents with osteogenesis imperfecta

Conditions: Osteogenesis Imperfecta

Summary: osteogenesis imperfecta (oi) is a rare genetic disorder of increased bone fragility and low bone mass. it is conceivable that children and adolescents with oi are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(apa). the hypothesis is that an adapted physique activity could improve access of activity for patients with osteogenesis imperfecta (oi). the aim of the study is to evaluate benefice of apa,improve aerobic capacity, cardiovascular and bone benefits, and gain of quality of life. children with oi between 6 and 18 years old will have a program of supervised "adapted training program" during one year. the program is adapted at each individual and without risk for the patient.


Eligibility criteria:
inclusion criteria: * child with osteogenesis imperfecta * child followed in the reference centre for constitutional bone diseases in the hôpital femme mère enfant * parent (s) / legal guardian who has been informed of the study and has accepted participation in the study by signing the consent. * patient benefiting from a social security scheme exclusion criteria: * medical and surgical contraindications to adapted physical activity.

Keywords: osteogenesis imperfecta adapted sport quality of life
clinical study on the safety and effectiveness of nk cells/combined monoclonal antibodies in the treatment of hematological malignancies

Conditions: Hematological Malignancies

Summary: clinical study on the safety and effectiveness of nk cells/combined monoclonal antibodies in the treatment of hematological malignancies

this is a single arm, open-label, single-center study. this study is indicated for hematological malignancies. the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. primary objective is to explore the safety, main consideration is dose-related safety.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of aml per the us national comprehensive cancer network (nccn) clinical practice guidelines for acute myeloid leukemia (2016.v1); 2. relapsed or refractory aml (meeting one of the following conditions): 1. cr not achieved after standardized chemotherapy; 2. cr achieved following the first induction, but cr duration is less than 12 months; 3. ineffectively after first or multiple remedial treatments; 4. 2 or more relapses; 3. the number of primordial cells in bone marrow is \> 5% (by morphology), and/or \> 0.01% (by flowcytometry); 4. total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/l; 5. echocardiogram shows left ventricular ejection fraction (lvef) ≥50%; 6. no active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%; 7. estimated survival time ≥ 3 months; 8. ecog performance status 0 to 2; 9. patients or their legal guardians volunteer to participate in the studyand sign the informed consent. exclusion criteria: 1. history of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagicdiseases; 2. electrocardiogram shows prolonged qt interval, severe heart diseasessuch as severe arrhythmia in the past; 3. pregnant (or lactating) women; 4. patients with severe active infections (excluding simple urinarytractinfectionand bacterial pharyngitis); 5. active infection of hepatitis b virus or hepatitis c virus; 6. concurrent therapy with systemic steroids within 2 weeks prior toscreening, except for the patients recently or currently receiving in haledsteroids; 7. previously treated with any car-t cell product or other genetically- modified t cell therapies; 8. creatinine\>2.5mg/dl, or alt / ast \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; 9. other uncontrolled diseases that were not suitable for this trial; 10. patients with hiv infection; 11. any situations that the investigator believes may increase the risk ofpatients or interfere with the results of study.
study to assess the kinetic of the analgesic effect and tolerability of eschscholtzia californica versus ibuprofen and placebo in the treatment of pain after surgery of the third molar

Conditions: Pain

Summary: study to determine the kinetic of the analgesic effect of 500 mg and 1000 mg of eschscholtzia californica per os and placebo in patients undergoing dental surgery over an observation period of 6 hours. in a secondary analysis, kinetic of analgesic effect comparison between eschscholtzia californica 500 mg, 1000 mg and ibuprofen 200 mg


Eligibility criteria:
inclusion criteria: * male or female above 18 or below 61 years old * patient having to undergo a third molar removal from the lower jaw under local troncular anesthesia (articaine + adrenaline) * type of inclusion of the molar: * molar in the sub-mucosa: type ii * molar partially impacted in the bone: type iii * patient suffering from at least moderate to severe pain after surgical removal of an impacted third molar, defined by a 4 point verbal rating scale * patient's informed consent in accordance with the french legislation * patient affiliated to the social security system exclusion criteria: * pregnant or nursing female or female of childbearing potential not using a medically approved method of contraception like oral contraception or intrauterine contraceptive device * patient with any pathology inducing a chronic pain * patient having taken any drug with analgesic properties in the 24 hours previous to the administration of the study drug * patient with concomitant administration of other non-steroid anti-inflammatory drug(s) (nsaids) or analgesic agents * patients treated by an antibiotic different from those required for the dental surgery which administration is started 48 hours prior to the tooth removal * patient with significant peri-operative complication judged by the investigator * patient with anti-coagulants concomitant treatment (including heparin) * patient with severe hepatic or renal insufficiency which judged to be regarded as clinically relevant by the investigator or any known clinically significant disease which may induce a risk for the patient in participating to the trial * patient with mental disturbance * patient with non controlled diabetes * patient with acute infections * patient with respiratory insufficiency, asthma * patient unable to comply with the protocol * patient having taken part in a clinical trial in the past month or already participating in another trial * patient deprived of their freedom by a judicial or administrative decision * adults under guardianship * persons hospitalized in medical or social establishments * patients in emergency situation * patient with a known or suspected hypersensitivity to the trial medication, to ibuprofen, paracetamol, anesthetic used (articaine, adrenaline), to the preventive antibiotic treatment (penicillin, macrolides) post study exclusion period: the patient will not be able to participate in any other trial for a period of two weeks after the end of this trial
effectiveness of a pressure indicator guided and a conventional bandaging in treatment of venous leg ulcer

Conditions: Venous Insufficiency

Summary: objective of this study are to compare the interface pressure by applying ordinary elastic bandage (oeb) and cpg-eb. in addition, investigators compared the percentage of patients who could apply the optimal pressure with oeb and cpg-eb.

for treatment of venous ulcer, it was shown that compression bandaging of 35-45 mmhg sub-bandage pressure at the ankle was shown in several studies to be safe and effective.the efficacy of compression bandage considerably depends on the applied pressure and it is therefore largely dependent on the individual applying bandages. the lower pressure leads to treatment failure while the higher pressure leads to skin complication. the use of objective devices to proof that the bandage is sufficiently applied is not available for every patients. to help the patients to apply the bandage with optimal pressure, investigators developed the customized pressure guide elastic bandage (cpg-eb) by using sub-bandage pressure guidance. objective of this study are to compare the interface pressure by applying ordinary elastic bandage (oeb) and cpg-eb. in addition,investigators compared the percentage of inexperienced staffs who could apply the optimal pressure with oeb and cpg-eb.

Eligibility criteria:
inclusion criteria: * patients with chronic venous insufficiency ceap (clinical, etiologic, anatomic, and pathophysiologic) c4,c5 and c6 exclusion criteria: * patients who can not perform bandaging by themselves

Keywords: venous insufficiency compression bandaging
a brief laboratory-based hypnosis session for pain in sickle cell disease

Conditions: Sickle Cell Disease

Summary: this pilot study will assess the effects of a brief laboratory-based guided imagery procedure on responses to pain in patients with sickle cell disease (scd) and healthy controls.


Eligibility criteria:
inclusion criteria: 1. healthy control or with a diagnosis of sickle cell disease 2. age 13 or older 3. african-american 4. subject is able to provide informed signed consent 5. subject is able to follow instructions exclusion criteria: 1. any known acute or chronic illness that in the judgment of the investigator, may compromise subject safety or data integrity 2. neurologic disorders affecting sensation 3. skin abnormality/abrasion over sites of stimulus 4. under 13 years of age 5. unable to follow instructions

Keywords: pain perception autonomic nervous system sickle cell disease hypnosis guided imagery
empower: randomized trial of online chronic pain management program to reduce reliance on opioid analgesic medications

Conditions: Chronic Pain

Summary: this is a 10-month internet-based randomized controlled trial to evaluate whether an online chronic pain management program ("e-health") can assist with reduced opioid reliance in chronic pain patients. about half of the eligible participants will receive access to the e-health program in addition to their standard chronic pain treatment; the other half will just continue receiving their standard chronic pain treatment.

this study will determine whether an innovative, accessible e-health intervention can assist with reduced opioid reliance in chronic pain patients, which can, ultimately, reduce risks of unintended opioid overdose and death. importantly, the study will contribute to a better understanding of the mechanisms contributing to opioid use reduction while managing pain. the findings may assist in developing treatment options for a population at risk for opioid adverse effects. potential participants will be identified through electronic health record (ehr) queries at participating sites. participants will be assessed at baseline, at the end of the 4-month treatment period, and at 6 months following end-of-treatment through an electronic data capture system accessed by the participants. other outcome data will be obtained from the participant's ehr data.

Eligibility criteria:
inclusion criteria: * be 25-80 years of age * be able to understand the study, and having understood, provide informed consent in english * have a daily average prescribed med ≥ 20 mg over a recent three-month period * have a chronic pain-related diagnosis * self-report current use of opioid medication(s) to treat pain * have a brief pain inventory pain intensity score ≥3 * have internet access and a working email account exclusion criteria: * be anyone who, in the judgment of study staff, would be unlikely to complete the study (e.g., planning to change to a different primary care clinic, have a terminal illness, etc.) * be unwilling/unable to complete the webneuro assessments * be pregnant * be a prisoner

Keywords: opioid therapy web-based intervention self-management
selective neuromuscular electrical stimulation on vmo

Conditions: Patellofemoral Pain Syndrome; Electric Stimulation

Summary: the purpose of this study is analyze the immediate effect of selective neuromuscular electrical stimulation of vastus medialis obliquus (vmo) in the electrical activity of vmo and vastus lateralis (vl) and in the isokinetic performance of women with patellofemoral pain syndrome.


Eligibility criteria:
inclusion criteria: * for healthy group: * with no history of osteomyoarticular lesion or surgery in the lower limbs in the previous six months * non-corrected neurological, vestibular, visual and/or hearing impairment * for patellofemoral pain syndrome group: * clinical diagnosis of patellofemoral pain syndrome * absence of other disorders in the knee * refer pain at leafs two of the following activities: when remain seated for a long period, squat, kneel and go up or down stairs. exclusion criteria: * individuals experiencing pain during collection procedures * do not perform exercises as instructed by the researches
effectiveness of group and individual training in eft for patients in remission from melanoma

Conditions: Melanoma (Skin)

Summary: serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. the adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. emotional freedom techniques (eft) has demonstrated efficacy in treating anxiety, depression, and ptsd. this study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission.

serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. the adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. emotional freedom techniques (eft) has demonstrated efficacy in treating anxiety, depression, and ptsd. this study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission. specifically, the study aims: 1. to assess the effect of instruction and practice of eft on illness perception, fear of cancer recurrence, and wellbeing. 2. to assess whether the social support provided by eft instruction in a group setting makes this efficient mode of implementation non-inferior or even beneficial in comparison to personal instruction. 3. to describe the emotions related to life events reported by patients in connection with the appearance and location of melanoma.

Eligibility criteria:
inclusion criteria: * melanoma diagnosis over six months prior to the study; confirmed by clinical, dermoscopic examination and pathology results exclusion criteria: * in active treatment for melanoma * schizophrenia * epilepsy * other malignant disease
evaluation of the effects of treatment with bioarginin c in adult subjects belonging to the post-covid day hospital

Conditions: Fatigue Syndrome, Chronic; Inflammation

Summary: long covid could be much more frequent than it is thought to be. few dwell on the great problem represented by the post covid syndrome. the virus often leaves important marks on our body, and those who recover face problems of various kinds: chronic fatigue, shortness of breath, dry cough, headache, cognitive difficulties. on the duration and resolution of this syndrome, now recognized as a highly debilitating condition, there are still no great answers: for this reason it is always important to emphasize that contracting covid, even in a not serious form, still means exposing oneself to long-term risks that are still not well codified by the scientific community. guidelines and more tools are expected to best assist these patients.


Eligibility criteria:
inclusion criteria: subjects with proven positivity to the molecular test for sars-cov2 with demonstration of microbiological healing patients discharged from fpg or other hospital structures; or only contact in ps; or home management age: range 20-60 years fatigue operationalized as an affirmative answer to item "7" (ces-d) exclusion criteria: pharmacological therapies with possible interactions with the mechanisms / processes under study (e.g. antihypertensive drugs, cortisone drugs, nsaids, immunosuppressants, nitrates)
homeopathic treatment of children suffering from pfapa

Conditions: Periodic Fever Syndrome

Summary: periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (pfapa) syndrome is frequently diagnosed in young children. fevers recurring at a nearly predictable rate every three to eight weeks are the signature symptom of pfapa syndrome. pfapa is an acquired autoinflammatory disorder, which recurs in association with at least one sign of aphthous stomatitis, pharyngitis, and cervical lymph node enlargement. the aim of this retrospective case report is to gain an impression of the course of disease during individualized homeopathic treatment in children suffering from pfapa.

in this retrospective study, the investigators collected the history and symptoms of 13 consecutive pfapa patients. the investigators also described the individually chosen homeopathic medicinal products (hmps) used, as well as the course of the disease. clinical outcome of case reports was assessed using the "modified naranjo criteria for homeopathy-causal attribution inventory". eight points are taken as the threshold for the possible correlation between homeopathic therapy and improvement of symptoms or cure in chronic cases

Eligibility criteria:
inclusion criteria: children suffering from fever with at least one of the symptooms of pfapa besides fever exclusion criteria: parents not willing to sign informed consent.

Keywords: pfapa periodic fever homeopathy naranjo criteria
ultrasound and endometrial hyperplasia

Conditions: Endometrial Hyperplasia

Summary: the investigators hypothesize that endometrial thickness will be a significant predictor of endometrial hyperplasia in a postmenopausal female population with metabolic syndrome: diabetes and/or insulin resistance, hypertension, and obesity.

the objective is to identify the utility of ultrasound as a screening test for endometrial hyperplasia and cancer in an "at risk" cohort. endometrial carcinoma is an understudied cancer. this study will provide benefit regardless of its outcome, because it will be the first prospectively designed screening trial in an asymptomatic population.

Eligibility criteria:
inclusion criteria: * postmenopausal obese subjects, who have diabetes or a prediabetic state, or hypertension exclusion criteria: * women who have had a hysterectomy
procalcitonin for predicting serious bacterial infection in infants less than 3 months

Conditions: Fever; Bacterial Infection

Summary: the primary objective is to study the value of serum procalcitonin as a predictive marker for severe bacterial infection in febrile infants. 2200 febrile infants aged less than 3 months will prospectively be included. all infants will have a measure of procalcitonin concentrations. comparison of the mean value of procalcitonin concentration in infants with and without serious bacterial infection. evaluation of the area under the roc for procalcitonin concentration.

serious bacterial infections are often difficult to detect in infant with fever without source. procalcitonin is a better blood marker of infection than white blood cell count and possibly than c-reactive protein. this could lead to a reduction in antibiotic prescription. our objective is to evaluate the impact of procalcitonin result on antibiotic prescription in children 1 to 3 month old with fever without source and our hypothesis is that it will lower the antibiotic prescription rate.

Eligibility criteria:
inclusion criteria: * infant older than 7 days old and less than 3 months old. * fever (defined by a rectal temperature greater than or equal to 38°c) * emergency consultation exclusion criteria: * infants with a previously identified immunodeficiency or chronic disease, * antibiotic treatment within the previous 48 hours

Keywords: fever infant procalcitonin serious bacterial infection
heartlogic france study: heart failure patients managed with the heartlogic algorithm

Conditions: Heart Failure

Summary: heart failure (hf) is a chronic disease that leads to numerous rehospitalisations and affects more than one million people in france. the main objective of this prospective multicentric french study is to describe the annual rate of unplanned hospitalisations for heart failure in a cohort of patients managed by a heartlogic algorithm. patients will be included if they fulfill the following requirements 1/patient implanted with a cardiac defibrillator with or without resynchronisation with the heartlogic index (resonate family, boston scientific); 2/history of heart failure (left ventricular ejection fraction ≤40 %; or at least one episode of clinical heart failure with elevated nt pro bnp≥450 ng/l). if a heartlogic index ≥16 is noticed, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment.

heart failure (hf) is a chronic disease that leads to numerous rehospitalisations and affects more than one million people in france. the main objective of this prospective multicentric french study is to describe the annual rate of unplanned hospitalisations for heart failure in a cohort of patients managed by a heartlogic algorithm. 310 patients will be included if they fulfill the following requirements 1/patient implanted with a cardiac defibrillator with or without resynchronisation with the heartlogic index (resonate family, boston scientific); 2/history of heart failure (left ventricular ejection fraction ≤40 %; or at least one episode of clinical heart failure with elevated nt pro bnp≥450 ng/l). the heartlogic index will be monitored remotely on a weekly basis for 12 months and in case of heartlogic index ≥16, the local investigator will contact the patient for assessment and adjust hf treatment as necessary. the primary endpoint is unscheduled hospitalization for hf. a blind and independent committee will adjudicate the events. blood samples will be collected for biobanking, and quality of life will be assessed.

Eligibility criteria:
inclusion criteria: * patient implanted with a cardiac defibrillator, with or without resynchronization, enabled with the heartlogic index (resonate family, boston scientific) * history of heart failure (left ventricular ejection fraction ≤40 %; or at least one episode of clinical heart failure with elevated nt pro bnp≥450 ng/l) exclusion criteria: * concomitant presence of a heart failure device other than cardiac resynchronisation such as a left ventricular assist device or a device for modulating cardiac contractility. * heart transplant project, or heart transplant patient * glomerular filtration rate \<30 ml/mn/m2 or dialysis, * life expectancy ≤ 6 months * remote monitoring of heartlogic is not possible. * refusal to take medication for heart failure * patient with a mechanical heart valve

Keywords: implantable cardioverter defibrillator quality of life